Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Walking With Overground Robotic Exoskeleton Device to Increase Behavioral Responsiveness in Patients With Disorders of Consciousness (WALK DOC) (WALK DOC)

13 luglio 2026 aggiornato da: Chad, Swank, Spaulding Rehabilitation Hospital

The goal of this observational study is to learn whether walking with an overground robotic exoskeleton (ORE) can improve responsiveness and brain activity in adults with disorders of consciousness (DoC) during inpatient rehabilitation after a severe brain injury. Participants include adults ages 18-70 who are in a coma, unresponsive wakefulness syndrome, or minimally conscious state and are receiving rehabilitation care at Spaulding Rehabilitation Hospital.

The main questions it aims to answer are:

  • Does using an ORE improve behavioral responsiveness compared with lying down, sitting, or standing?
  • Does using an ORE increase brain activity, and are changes in brain activity related to changes in responsiveness?
  • Is ORE therapy safe, tolerable, and feasible for people with DoC during inpatient rehabilitation?

Researchers will compare participants' responses during sessions involving lying down, sitting, standing, and walking with the robotic exoskeleton to see if the exoskeleton leads to greater improvements in responsiveness and brain activity.

Participants will:

  • Complete an initial screening session to determine whether they can safely use the robotic exoskeleton.
  • Participate in six study sessions over about two weeks during their rehabilitation stay. During these sessions, participants will complete activities that may include lying down, sitting, standing, and walking with a robotic exoskeleton. The order of activities will be assigned at random.
  • Have their level of responsiveness measured before and after each session using a standardized assessment called the Coma Recovery Scale-Revised (CRS-R).
  • Wear a wireless EEG cap before, during, and after sessions so researchers can measure brain activity.
  • Have their heart rate and safety monitored throughout the study sessions.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

18

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Stati Uniti
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02129
        • Spaulding Rehabilitation Hospital
        • Investigatore principale:
          • Chad Swank, PhD
        • Contatto:
          • Clinical Research Project Manager
          • Numero di telefono: 6179526354
          • Email: jzhang71@mgb.org

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population will be selected from inpatient rehabilitation patients with disorders of consciousness (DoC) receiving medical care and rehabilitation at inpatient rehabilitation units in an inpatient rehabilitation facility (IRF) or long-term acute care hospital (LTAC). Patients will be identified from those admitted for inpatient rehabilitation and screened using the eligibility criteria outlined, through the hospital's standard clinical and medical record review processes.

Descrizione

Inclusion Criteria:

  • Medical diagnosis of disorders of consciousness (DoC) confirmed by the Coma Recovery Scale - Revised (CRS-R), including patient classified as Minimally Conscious State (MCS), Unresponsive Wakefulness Syndrome (UWS), or coma.
  • Acute/Subacute phase of recovery
  • Medically stable as deemed by a physician
  • Undergoing medical care and rehabilitation at hospital
  • Both sexes and all races and ethnicities
  • Meet the robotic exoskeleton frame limitations
  • Continence of or a program for bladder and bowel management

Exclusion Criteria:

  • Concurrent spinal cord injury (SCI)
  • Degenerative diagnoses, pre-morbid developmental disability, significant psychological diagnosis such as bipolar disorder and schizophrenia
  • Any contraindication to use the exoskeleton device, including:
  • Contracture in the hip, knee and ankle joints.
  • Uncorrectable Equinovarus foot deformation.
  • Severe muscular spasticity of the lower extremities (Modified Ashworth Scale Grade 3 higher).
  • Fractures or incomplete bone junctions in the spine, pelvis, and/or lower extremities.
  • Osteoporosis or lower bone mineral density -3.5, and history(ies) of osteoporotic fracture(s).
  • Skin disorders including Stage I pressure injuries at the hip, lower limbs, and Exoskeleton contact areas, according to the National and European Pressure Ulcer Classification System (NPUAP-EPUAP).
  • Inability to communicate with an Assistant due to cognitive and language disorders.
  • Severe arthritis, acute arthritis, or synovitis after total or partial lower limb joint replacement.
  • Orthostatic hypotension, essential hypertension, and a condition in which blood pressure is not controlled.
  • Myocardial infarction or angina or ischemic heart disease within the last 6 months.
  • Tachycardia, bradycardia, arrhythmia and other cardiac functions that are not controlled.
  • Uncontrolled autonomic dysreflexia (AD).
  • Uncontrolled diabetes.
  • Infectious diseases or other serious complications.
  • Uncorrectable leg length discrepancy over 2 cm when using additional correction tools.
  • III-IV spine scoliotic deformity.
  • Pregnant women should consult their physician prior to use.
  • Amputations and lower limb prostheses.
  • Morphological characteristics out of the device limitations.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Patients with Disorders of Consciousness
Adults with a disorder of consciousness, such as coma, unresponsive wakefulness syndrome, or a minimally conscious state, who are receiving inpatient rehabilitation after a severe brain injury.
Dispositivo: Overground Robotic Exoskeleton (ORE)
Participants will receive overground robotic exoskeleton-assisted standing and walking as part of inpatient rehabilitation. Following a screening session to assess device fit and tolerance, participants complete supervised ORE sessions. The intervention is distinguished by the use of assisted overground walking and upright mobility in individuals with disorders of consciousness and is evaluated in relation to behavioral responsiveness, brain activity, safety, tolerability, and feasibility.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Coma Recovery Scale-Revised (CRS-R)
Lasso di tempo: From enrollment to end of study at 2 weeks
The Coma Recovery Scale-Revised (CRS-R) is a 23-item behavioral assessment used to evaluate consciousness in patients with brain injuries. It measures auditory, visual, motor, oromotor, and communication functions. The total score ranges from a minimum of 0 to a maximum of 23, with higher scores indicating a higher level of neurobehavioral function and conscious awareness. CRS-R scores help characterize a patient's level of consciousness, including coma, vegetative state/unresponsive wakefulness syndrome, or minimally conscious state.
From enrollment to end of study at 2 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Disability Rating Scale (DRS)
Lasso di tempo: Discharge from inpatient rehabilitation, an average of 8 weeks
The Disability Rating Scale (DRS) is an 8-item clinical tool used to track a patient's recovery from a moderate-to-severe traumatic brain injury (TBI) from the coma stage through to community living. Scores range from 0 (no disability) to 29 (extreme vegetative state)
Discharge from inpatient rehabilitation, an average of 8 weeks
CARE (Continuity Assessment Record and Evaluation)
Lasso di tempo: From inpatient admission through discharge from inpatient stay, assessed at routine intervals.

The CARE (Continuity Assessment Record and Evaluation) tool is a standardized CMS assessment used to measure the medical, functional, cognitive, and social needs of Medicare post-acute care patients

The assessment evaluates four major domains:

  • Medical Domain: Monitors changes in severity, active treatments, pain, and pressure ulcers.
  • Functional Domain: Evaluates self-care and mobility prior to and during the illness (e.g., assessing mobility and daily living activities).
  • Cognitive Domain: Assesses functional cognition, cognitive impairments, and factors affecting outcomes.
  • Social/Environmental Factors: Reviews living situations, support systems, and discharge planning needs.
From inpatient admission through discharge from inpatient stay, assessed at routine intervals.
Electroencephalogram (EEG)
Lasso di tempo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Cortical activity will be recorded continuously during the study sessions using a 24-channel mobile electroencephalography (EEG) system. Key positional changes will be marked in the EEG recording. EEG spectral power, including power within predefined brain wave frequency bands, will be evaluated before, during, and after positional changes. Changes in these measures will be used to evaluate cortical activity across study conditions. EEG frequency measures will be reported in hertz (Hz).
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Event-Related Potential (ERP) - N100
Lasso di tempo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Event-related potentials (ERP) will be recorded before and immediately after each study session. N100 ERP responses will be assessed, reflecting auditory sensory processing. For each response, the timing of the brain response (peak latency) will be measured. ERP latency measures will be reported in milliseconds (ms).
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Event-Related Potential (ERP) - P300
Lasso di tempo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Event-related potentials (ERP) will be recorded before and immediately after each study session. P300 ERP responses will be assessed, reflecting basic attention processing. For each response, the timing of the brain response (peak latency) will be measured. ERP latency measures will be reported in milliseconds (ms).
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Event-Related Potential (ERP) - N400
Lasso di tempo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Event-related potentials (ERP) will be recorded before and immediately after each study session. N400 ERP responses will be assessed, reflecting cognitive processing. For each response, the timing of the brain response (peak latency) will be measured. ERP latency measures will be reported in milliseconds (ms).
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
Rate of Adverse Events (AE)
Lasso di tempo: Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
Safety of the study will be measure via Rate of Adverse Events (AE). Reported exoskeleton-emergent AE will include: increase in pain behavior or agitation, disconcerting changes in cardiovascular function (e.g., sudden drop in blood pressure), skin irritation or orthopedic injuries caused by the robotic exoskeleton device, sudden changes in alertness (e.g., somnolence), autonomic storming, and seizure activity.
Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
Heart Rate Reserve (HRR)
Lasso di tempo: Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
Heart Rate Reserve (HRR) will be recorded as a measure of cardiovascular tolerability during the intervention. A heart rate monitor will be used to record the amount of time spent in each heart rate zone during ORE sessions: very light (<30% HRR), light (30-39%), moderate (40-59%), vigorous (60-89%), and near maximal (>90%).
Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
Session completion rate (SCR)
Lasso di tempo: Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
Session completion rate (SCR) will be used to assess the feasibility of completing the scheduled overground robotic exoskeleton sessions. Feasibility will be measured by the percentage of scheduled sessions that each participant completes. Based on prior clinical experience delivering exoskeleton sessions to patients with disorders of consciousness, successful session completion will be defined as completing at least 75% of the scheduled overground robotic exoskeleton sessions. For any missed session, the reason for the missed session and whether the session was rescheduled or made up will be documented. The time needed to complete any make-up sessions will also be recorded. These data will help determine whether the intervention schedule is practical and manageable for participants.
Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Spaulding Rehabilitation Hospital

Investigatori

  • Investigatore principale: Chad Swank, PhD, Spaulding Rehabilitation Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 aprile 2028

Completamento dello studio (Stimato)

1 ottobre 2028

Date di iscrizione allo studio

Primo inviato

7 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 luglio 2026

Primo Inserito (Effettivo)

16 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2026P000662
  • HT94252510986 (Altro numero di sovvenzione/finanziamento: CDMRP)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Disturbi della coscienza

Prove cliniche su Overground Robotic Exoskeleton (ORE)

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Lebanon

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi